RARE - Company ID 0001515673
The table below shows Ultragenyx Pharmaceutical Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $175.00M | $202.51M | $176.31M | $127.06M | $150.62M | $480.69M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $121.00M | $112.54M | $124.46M | $98.84M | $93.30M | $105.98M |
| Inventory | $55.00M | $52.20M | $46.50M | $46.03M | $43.33M | $40.14M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $657.00M |
| $643.21M |
| $719.79M |
| $699.15M |
| $799.61M |
| $964.64M |
| Property, plant & equipment | $239.00M | $249.96M | $255.76M | $260.91M | $272.45M | $278.71M |
| Goodwill | $44.00M | $44.41M | $44.41M | $44.41M | $44.41M | $44.41M |
| Total assets | $1.30B | $1.19B | $1.31B | $1.31B | $1.54B | $1.62B |
| Accounts payable | $42.00M | $40.57M | $34.24M | $47.45M | $35.99M | $59.81M |
| Total current liabilities | $325.00M | $340.02M | $293.24M | $291.67M | $285.01M | $272.87M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $1.52B | $1.17B | $1.15B | $1.16B | $1.18B | $1.19B |
| Retained earnings | -$4.72B | -$4.40B | -$4.22B | -$4.11B | -$3.82B | -$3.69B |
| Total equity | -$236.00M | $9.16M | $151.29M | $144.25M | $346.83M | $432.42M |